BioGaia’s results for the third quarter to exceed market expectations
(Figures in the brackets refer to the same period the previous year)
During the third quarter of 2022, BioGaia's sales have been positively impacted by increased demand, mainly in the Americas, as well as positive currency effects.
For the third quarter, sales are preliminarily estimated at SEK 258 million (174), an increase of 48%. The operating profit for the third quarter is preliminarily estimated at SEK 94 million (67), an increase of 40%.
BioGaia publishes the interim report for quarter three on Friday, October 21, 2022, at 08:00 am CEST, followed by an audiocast at 09:30 am CEST.
Subscribe to BioGaia press releases here
Alexander Kotsinas, CFO
Phone: +46 (0) 735 00 11 11
Mikaela Idermark Stern, Corporate Communications
Phone: +46 (0) 730 95 61 50
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com
This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 08:00 am CEST on October 17, 2022.